Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that testosterone therapy can enhance sexual satisfaction and mood in surgically menopausal women on oestrogen, though ongoing monitoring and research are needed to assess long-term safety and effects in other groups.

This study found that cortexolone 17α-propionate (clascoterone) effectively inhibited androgen receptor-regulated transcription and IL-6 synthesis in scalp cells, potentially making it a promising candidate for topical treatment of androgenetic alopecia.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

This study found that progesterone pretreatment in rats potentiated the effect of ethanol on mesocortical dopamine levels, suggesting an influence of neuroactive steroids on ethanol's action.

In this mouse study, researchers found that nanoparticles loaded with umbilical cord-derived stem cell membranes and minoxidil enhanced hair growth by improving drug solubility and transdermal delivery, increasing VEGF, IGF-1, MKI67, and CTNNB protein levels in skin tissue compared to regular minoxidil.

This study found that the new minoxidil formulation, DC0120, was noninferior to the marketed product ALOSTIL® in promoting hair growth for men with androgenetic alopecia over 16 weeks.

Dutasteride injections can help treat hair loss in men and women.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This study developed and validated a comprehensive method using mass spectrometry to profile sex (pro)hormones in plasma, with results showing reliable calibration and detection of 31 analytes in samples from pre- and postmenopausal women and men, while addressing potential over- or underestimations in analyte concentrations.

This letter provides no study results about minoxidil 3% lotion for beard enhancement but instead shares author and affiliation details for the published research.

This study found that combining 17α-estradiol 0.01% with minoxidil 2% offered no statistically significant advantage over minoxidil alone for treating female pattern hair loss and may increase the risk of menstrual irregularities.

This study found that the phytosterols β-sitosterol, stigmasterol, and campesterol have low-to-negligible inhibitory activity against steroidal 5α-reductase type 2 compared to the synthetic inhibitor dutasteride, with β-sitosterol showing the highest activity among the tested phytosterols.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.

In this study, lecithin-based microparticle formulations of minoxidil showed enhanced skin penetration and comparable hair growth effectiveness to commercial products in mice, while minimizing skin irritation often seen with standard minoxidil solutions.

This study found that progesterone derivatives with chlorine or bromine substituents were effective in inhibiting 5α-reductase activity in human prostate and exhibited antiandrogenic effects in hamster flank organs.

This study found that in men with androgenetic alopecia, a combination therapy of oral dutasteride and minoxidil was well tolerated and resulted in hair stabilization for nearly all participants by month 6, with 71.4% showing improvement by month 9.

In this study, maslinic acid applied topically was observed to stimulate hair growth in mice comparably to minoxidil, primarily activating pathways like Wnt/β-catenin, and suggesting a link between hair growth and cilia activity.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

This review discusses nonsteroidal selective androgen receptor modulators and their potential therapeutic applications but reports no new clinical findings.

This study observed that DMSO-modified liposomes enhanced the topical delivery of finasteride, improving hair follicle density and growth phase ratio in a rat model of testosterone-induced alopecia.

This review discusses hormone replacement therapy for menopausal women, emphasizing DHEA's unique ability to convert into sex steroids only in targeted tissues, and reports no new clinical results.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.

This study found that compounded topical minoxidil was associated with higher adherence, fewer side effects, and more clinical improvement in Black women compared to over-the-counter minoxidil.